Kathrin I Foerster

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Antiretroviral Therapy

Middle Cerebral Artery

Top Venues

Clinical pharmacokinetics

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics 63 (4) (2024)
Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics 63 (4) (2024)
Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics 63 (4) (2024)
Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics 63 (4) (2024)
Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster, Juergen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter Emil Haefeli
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical pharmacokinetics (2024)
Amin Muhareb, Antje Blank, Andreas Daniel Meid, Kathrin I Foerster, Felicitas Stoll, Juergen Burhenne, Walter Emil Haefeli, Gerd Mikus
CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults. Clinical pharmacokinetics (2023)
Manuel Kraft, Kathrin I Foerster, Felix Wiedmann, Max Sauter, Amelie Paasche, Pablo L Blochberger, Baran Yesilgöz, Yannick L'hoste, Norbert Frey, Walter Emil Haefeli, Juergen Burhenne, Constanze Schmidt
Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue. Pharmaceutics 14 (4) (2022)
Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Florian Selt, Sara Najafi, Simay Ayhan, Xenia F Gerloff, Nina Hofmann, Isabel Büdenbender, Lukas Schmitt, Kathrin I Foerster, Juergen Burhenne, Walter Emil Haefeli, Andrey Korshunov, Felix Sahm, Cornelis M van Tilburg, David T W Jones, Stefan M Pfister, Deborah Knoerzer, Brent L Kreider, Max Sauter, Kristian W Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde
The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models. Neuro-oncology (2022)
Michael Bieber, Kathrin I Foerster, Walter Emil Haefeli, Mirko Pham, Michael K Schuhmann, Peter Kraft
Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood-Brain Barrier Damage and Inflammation. International journal of molecular sciences 22 (18) (2021)
Kathrin I Foerster, Simon Hermann, Gerd Mikus, Walter Emil Haefeli
Drug-Drug Interactions with Direct Oral Anticoagulants. Clinical pharmacokinetics 59 (8) (2021)